CCM
VVOS icon

Connective Capital Management’s Vivos Therapeutics VVOS Stock Holding History

Connective Capital Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$620K – 90
2025
Q3 		$620K Buy
+200,000
New +$906K 0.57% 31

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AWA
Acorn Wealth Advisors Grand Blanc, Michigan $343M AUM 15.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connective Capital Management's VVOS Position: Q4 2025 in Review

Connective Capital Management sold out of Vivos Therapeutics (VVOS) in Q4 2025, closing a stake of 200,000 shares — an estimated $620K sold.

Connective Capital Management first reported a position in VVOS in Q3 2025 and held it in 1 quarter. The position peaked at $620K in Q3 2025. 19 funds tracked by Wall St. Rank hold VVOS as of Q4 2025.

  • Connective Capital Management reported no remaining Vivos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Connective Capital Management sold 200,000 Vivos Therapeutics shares in Q4 2025, an estimated $620K.
  • Connective Capital Management first reported a position in Vivos Therapeutics in Q3 2025 and held it in 1 quarter.
  • Connective Capital Management's Vivos Therapeutics position peaked at $620K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2025.

Based on Connective Capital Management's 13F filing for Q4 2025, filed 19 Feb 2026.